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Background: Necrotizing pancreatitis is a common condition with high mortality; the acute care surgeon
is frequently consulted for management recommendations. Furthermore, there has been substantial
change in the timing, approach, and frequency of surgical intervention for this group of patients.
Methods: In this article we summarize key clinical and research developments regarding necrotizing
pancreatitis, including current recommendations for treatment of patients requiring intensive care and
those with common complications. Articles from all years were considered to provide proper historical
context, and most recent management recommendations are identiﬁed.
Results: Epidemiology, diagnosis, treatment in the acute phase, and complications (both short-term and
long-term) are discussed. Images of surgical interventions are included from our institutional experience.
Conclusion: Necrotizing pancreatitis management remains heavily based on clinical judgement, although
technological advances and clinical trials have made decision making more straightforward.
© 2020 Elsevier Inc. All rights reserved.
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Introduction
Acute pancreatitis is amongst the most prevalent gastrointestinal conditions in patients presenting to an emergency department in the United States, and the most common reason for
hospital admission.1 Although mild cases usually self-resolve with
supportive care, roughly 20% of these cases are categorized as
necrotizing pancreatitis. Necrotizing pancreatitis is diagnosed if a
signiﬁcant portion of the gland or surrounding tissue does not
enhance on contrasted computed tomography scan, a ﬁnding that
signiﬁcantly affects treatment strategies and prognosis.2e6 This
review aims to consolidate the current understanding of epidemiology, diagnosis, prognostication, treatment, and complications of
necrotizing pancreatitis.
Etiology
Etiologies for necrotizing pancreatitis are similar to those for
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acute pancreatitis, with gallstone disease being the most common
causative process in the United States, followed by alcohol abuse.1,2
The pathophysiology underlying acute pancreatitis is thought to be
related to inappropriate activation of proenzymes within the gland,
leading to pancreatic inﬂammation.7 If severe enough, this leads to
a systemic inﬂammatory response, leading to hypotension and
exacerbating pancreatic damage due to ischemia.7 Several molecular mechanisms play roles in pancreatic inﬂammation, including
release of nuclear factor-kappa B and release of various pro- and
anti-inﬂammatory cytokines. Nuclear factor-kappa B is thought to
link local inﬂammation with a systemic response, which can often
occur early in the disease course, manifesting with classic signs of
systemic inﬂammatory response syndrome.8 Anti-inﬂammatory
cytokines are released in response, but may have an undesired
inhibitory effect that allows for development of infection during a
period of relative immunosuppression.8
With regards to development of necrosis, speciﬁc mechanisms
are elusive, as necrosis is simply thought to be achieved when
pancreatic parenchyma has suffered enough insult that it cannot
recover. Some studies have investigated whether genetic predisposition affects rates of necrosis development, but results have
been inconclusive thus far. Alcohol abuse has been correlated with
necrosis development in some studies, but this has not been
deﬁnitively proven.9 Other etiologies of pancreatitis (anatomic

https://doi.org/10.1016/j.amjsurg.2020.08.027
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variants, autoimmune, hypertriglyceridemia, hypercalcemia, medications, snake bites, scorpion stings, etc.) occur infrequently and
have not been extensively studied with regards to development of
necrosis. Risk factors are related mainly to etiologic factors (gallstones, alcohol use, etc.) and patient demographics do not appear to
affect propensity for development of pancreatic necrosis. More
generally, if resuscitation of patients with severe pancreatitis is
suboptimal and leads to periods of hypotension and vasopressor
support, this can induce or exacerbate necrosis within the
gland.10,11 Necrosis may not be evident on very early imaging, but it
has been postulated that it is often developing prior to manifesting
radiographically.12 Thus, early recognition of systemic inﬂammatory response and adequate treatment is imperative in limiting
pancreatic necrosis, regardless of radiographic ﬁndings.

Epidemiology
Greater than 250,000 hospital admissions occur annually, and
this incidence is increasing.13 Several studies have estimated the
current economic burden of pancreatitis to be around $2.5
billion.1,13 Much of this is likely spent on the roughly 20% of
patients who develop necrotizing pancreatitis, as development
has been correlated with increased morbidity and mortality.
More extensive necrosis (as measured by contrast-enhanced
computed tomography) has been correlated with increased
morbidity, mortality, rate of infection, likelihood of debridement,
and multi-organ dysfunction.14e16 Less extensive necrosis (less
than 30% of the pancreas) is associated with signiﬁcant morbidity
(40%), but mortality, infection, and organ failure rates all have
been reported under 20%.15,16 When greater than 50% of the
pancreas is necrotic, rate of morbidity approaches 100%, mortality 40%, infection 50%, need for debridement 70%, and multiorgan dysfunction 65%.15,16 With regards to development of
pancreatic necrosis in patients with multiple episodes of
pancreatitis, there is no deﬁnitive evidence that more episodes
lead to more severe necrosis. Indeed, certain patients may have
the misfortune of experiencing severe acute pancreatitis with
extensive necrosis even during their ﬁrst episode of pancreatitis.
Many studies have investigated laboratory values as predictors of
necrosis development, but, to date, none have been robust
enough to tailor therapy to speciﬁc patients.17,18
Development of acute necrotic collections and walled-off necrosis are notable potential complications of necrotizing pancreatitis. Acute necrotic collections are deﬁned by revised Atlanta
classiﬁcation as associated ﬂuid collections in the presence of
necrosis less than 4 weeks after onset of pancreatitis, and walledoff necrosis developing greater than 4 weeks after onset.19 However, a recent study showed that walled-off necrosis may develop
sooner than Atlanta classiﬁcation deﬁnitions, with 43% of welldeﬁned collections shown on imaging within 3 weeks of onset.12
Up to 33% of patients with necrotizing pancreatitis will develop
infected necrosis.20 Infection of collections or the initial area of
necrosis markedly increases morbidity and mortality rates and
has traditionally mandated some form of drainage procedure.21e23
Another feared complication is hemorrhage, which occurs in
approximately 5% of patients with necrotizing pancreatitis, and is
thought to be due to inﬂammatory damage to peripancreatic
vessels leading to pseudoaneurysm formation.1 Rupture of these
pseudoaneurysms can lead to hemorrhagic shock and death
without deﬁnitive hemorrhage control (generally via angioembolization) and blood transfusion.12 Finally, up to 30% of patients
with necrotizing pancreatitis may have a main pancreatic duct
disruption, though deﬁnitive links to outcomes have not been
determined.24

Diagnosis
Three criteria are used to establish the diagnosis of acute
pancreatitis.25 The ﬁrst is abdominal pain, which is usually
epigastric or left upper quadrant in location. It may radiate to the
back, ﬂank or chest although this is non-speciﬁc. The pain can be
varied in intensity and may be described as dull and colicky.
However, none of these ﬁndings correlate with disease severity.
The ﬁrst onset of pain should be obtained in history taking, as this is
considered the true time of onset rather than when the patient
presented to the hospital.19
The second criterion for diagnosis is serum lipase levels greater
than three times the upper limit of normal. Serum amylase had
been previously used for diagnosis. However, levels typically rise
within a few hours of onset and return to normal after 3e5 days
and may never be elevated in approximately 20% of patients as
well.26,27 Thus, serum lipase has been found to be more speciﬁc and
is currently recognized as part of the diagnostic criteria for acute
pancreatitis.25 To be considered diagnostic, the levels must be 3
times the normal range of the laboratory performing the test. At
present there is no consensus regarding a standardized upper limit
of normal for serum lipase.
The ﬁnal criterion is radiologic imaging consistent with
pancreatitis. Contrast-enhanced computed tomography scan or
magnetic resonance imaging scan is not recommended on a routine
basis, but rather only for cases that remain unclear by the previous
two criteria, or if a patient fails to improve after 48e72 h of treatment to evaluate for pancreatic necrosis or ﬂuid collections and
determine the extent.25,28e30 In uncomplicated acute pancreatitis,
imaging will demonstrate homogenous enhancement with inﬂammatory changes of the peripancreatic fat. Pancreatic necrosis is
deﬁned radiographically by a failure of the pancreatic parenchyma
to enhance with intravenous contrast. If greater than 30% of the
parenchyma does not enhance, the diagnosis changes to necrotizing pancreatitis (Fig. 1).
It is also essential to assess for the presence of an associated
peripancreatic ﬂuid collection. Acute peripancreatic ﬂuid collections typically develop in the ﬁrst week, are homogenous on imaging, and are conﬁned by normal fascial planes. These ﬂuid
collections typically remain sterile and usually resolve without
intervention.5,19,31 Peripancreatic ﬂuid collections that persist
beyond 4 weeks are described as pseudocysts. If imaging demonstrates a heterogeneous ﬂuid collection associated with necrotizing
pancreatitis, the ﬂuid collection is deﬁned to be necrotic (Fig. 2).
When the collection is less than 4 weeks old, it is described as an
acute necrotic collection; if present for greater than 4 weeks and
contained within a wall of reactive tissue, it is described as walledoff necrosis.19 Presence of air within the ﬂuid collection or
pancreatic parenchyma is highly suspicious for infected necrosis
(Fig. 3). Delayed imaging at 5e7 days after onset is usually more
useful than initial imaging for distinguishing between these classes
of ﬂuid collections. Additionally, magnetic resonance imaging
(including magnetic resonance cholangiopancreatography), transabdominal ultrasonography, and endoscopic ultrasonography may
be useful for obtaining diagnosis. Magnetic resonance cholangiopancreatography has the beneﬁt of evaluating for ductal
communication with ﬂuid collections, as management strategies
may be altered by this distinction.19 In the case of suspected
infected pancreatic necrosis, ﬁne needle aspiration had been previously employed, with positive cultures used to conﬁrm diagnosis.
However, due to prohibitive false negative rates and the theoretical
risk of seeding of sterile necrosis, this method has fallen out of
favor. Radiographic ﬁndings in conjunction with clinical judgement
is now considered adequate for diagnosis.
Prediction of pancreatitis severity is controversial and has been
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attempted by multiple scoring systems, including the bedside index
of severity in acute pancreatitis (BISAP), acute physiology and
chronic health evaluation II (APACHE II), Ranson’s criteria, and
Balthazar computed tomography severity index, among others.
These scoring systems utilize various clinical, laboratory, and
radiographic ﬁndings to predict the severity of pancreatitis. Each
has utility, but must be considered only adjuncts to appropriate
clinical judgement. As this article focuses on necrotizing pancreatitis (and thus a mostly severe subset of pancreatitis), detailed
discussion of each scoring system is beyond the scope of this article.
Treatment
Non-surgical treatment of necrotizing pancreatitis initially does
not differ dramatically from that for acute pancreatitis without
necrosis. Early management is directed at early and aggressive
hydration to address hypovolemia due to ﬂuid sequestration in
pancreatic and peripancreatic tissue along with systemic inﬂammation.32e35 Initial volume repletion with isotonic crystalloid
should be at a rate of 250e500 mL/h, with lower rates necessary for
patients with precluding comorbidities.25 Ringer’s lactated solution
may be beneﬁcial in preventing and correcting systemic inﬂammatory response syndrome and electrolyte imbalance.34 During
repletion, repeat assessments of intravascular volume should be
made frequently, particularly during the ﬁrst 24 h. Non-responders
in the ﬁrst 6e12 h may not beneﬁt from continued aggressive
volume expansion.36 There remains no medication that speciﬁcally
and effectively treats pancreatitis.32,33
In the case of biliary pancreatitis, endoscopic retrograde cholangiopancreatography (ERCP) plays an important role.25 The current indications for ERCP in the setting of acute pancreatitis include
patients with a clinical picture consistent with cholangitis or evidence of ongoing biliary obstruction. In the setting of suspected
choledocholithiasis without convincing evidence of cholangitis or
complete biliary obstruction, magnetic resonance cholangiopancreatography or endoscopic ultrasonography may be
useful in conﬁrming diagnosis and need for ERCP. If concerned for
cholangitis or biliary obstruction, ERCP should be performed within
24 h of presentation. The risk of post-ERCP pancreatitis must be
considered, but should not prevent performance of the procedure if
it is necessary to relieve biliary obstruction. Additionally, several

Fig. 1. Acute necrotizing pancreatitis without associated ﬂuid collections imaged with
computed tomography scan. Note the fat stranding, implying inﬂammation, and lack of
contrast enhancement, implying necrosis due to inadequate perfusion. Imaging is from
initial presentation.

Fig. 2. Necrotizing pancreatitis with associated walled-off necrosis imaged with
computed tomography scan. Imaging is from roughly 3 weeks after initial presentation.

adjuncts exist to decrease the incidence of post-ERCP pancreatitis,
including prophylactic placement of pancreatic duct stents and
post-procedural administration of rectal non-steroidal anti-inﬂammatory drugs.37,38
Nutrition is a critical component in the management of the
patient with pancreatitis, and has been the subject of intense
debate. Historically, patients were kept without oral intake until
their condition clinically improved, they had resolution of inﬂammation on interval imaging, or until normalization of serum
amylase and lipase. This was all due to fear of worsening the
pancreatitis via pancreatic stimulation. These fears have since been
shown to be largely unfounded, and early feeding (within 24 h) is
recommended provided there is no other contraindication. In the
case of mild pancreatitis, a low residue and low-fat diet may be
initiated for the patient to consume as tolerated.39 Severely ill patients may require enteral feeding via nasogastric or nasojejunal
tubes. Nasogastric feeding had previously been discouraged for fear
of pancreatic stimulation and gastroparesis but has since been
demonstrated to be non-inferior to nasojejunal feeding.40

Fig. 3. Infected pancreatic necrosis imaged with computed tomography scan. Imaging
is from roughly 2 weeks after initial presentation.
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Another area of great debate is antibiotic administration for
pancreatitis. Currently, in the setting of necrotizing pancreatitis,
prophylactic antibiotics do not have a role.41,42 However, if patients
develop systemic signs of infection and other sources are effectively
ruled out, infected pancreatic necrosis must be considered. If
infected pancreatic necrosis is identiﬁed, antibiotics selected must
cover pancreatic and gastrointestinal organisms, including Gramnegative enteric bacteria, Gram-positive bacteria, and, less
frequently, anaerobes and fungi. First-line choices include carbapenems, with ﬂuoroquinolones as a secondary option, and metronidazole and antifungals reserved for cases with higher suspicion
for anaerobic or fungal infection. Appropriate treatment with
antibiotic therapy may obviate the need for surgical intervention in
a select group of patients. However, infected necrosis treated with
antibiotics alone has a high mortality rate, as one meta-analysis
demonstrated that 64% of patients treated conservatively for
infected pancreatic necrosis had a mortality of 12%.10
When medical management proves insufﬁcient for patients
with necrotizing pancreatitis, surgical management may become
pivotal to their outcome. Historically, patients with necrotizing
pancreatitis were treated with early laparotomy and open
necrosectomy. The morbidity and mortality associated with early
necrosectomy is signiﬁcant. In 1997, the concept of delayed intervention was introduced when Mier et al. randomized patients with
severe necrotizing pancreatitis to early (48e72 h) versus late (>12
days) necrosectomy and found that late necrosectomy did not increase mortality.43 Other studies have since made it clear that
delayed surgical intervention for necrotizing pancreatitis has a
mortality beneﬁt.44,45 Though intervention may be necessary for
indications other than pancreatic necrosis, such as intestinal
ischemia or abdominal compartment syndrome, delayed pancreatic intervention is the preferred approach today.
Additionally, minimally invasive interventions have largely
replaced open necrosectomy. In a landmark paper in 2010, the
“step-up approach” was demonstrated to have superior outcomes
in terms of major complications and mortality.46 This study
demonstrated that placement of percutaneous drains obviates the
need for major abdominal intervention in approximately one-third
of patients. The key to successful management when utilizing a
step-up approach is a coordinated effort between the interventional radiologist placing the drains and the surgical team, who
may need to utilize the drain tract for a minimally invasive
necrosectomy (Fig. 4). This represents, in many ways, an evolution
of the classic open ﬂank drainage approach, which provided wide,
dependent retroperitoneal drainage from either the left or right
side.
If percutaneous drainage fails, surgical drainage must be
considered. Minimally invasive options include video-assisted retroperitoneoscopic debridement (VARD) and endoscopic necrosectomy.28 In VARD, a previously placed percutaneous drain is used as
a guide for incision and dissection along its tract, with eventual
suctioning and removal of pancreatic necrosis (Fig. 5). Clearance of
infected tissue is immediate and usually thorough (Fig. 6). In
endoscopic necrosectomy entry to the retroperitoneum is gained
through the posterior gastric wall, the connection stented open,
and drains left between the retroperitoneum and gastric lumen
(Fig. 7). This approach has similar outcomes to VARD and obviates
the need for incisions, but requires more procedures to replace and
remove stents and drains. VARD and endoscopic necrosectomy
appear roughly equivalent in terms of mortality and overall major
complications, with VARD having a higher risk of pancreatic ﬁstula
formation and longer length of stay, and endoscopic necrosectomy
involving more procedures to replace and remove stents and
drains.28 Choosing between endoscopic necrosectomy and VARD is
ultimately dependent on patient-speciﬁc factors, including

anatomic considerations (e.g., stomach-necrosis interface or previous gastrointestinal surgeries), patient preference (e.g., number
of procedures or prolonged need for external drains), and experience levels of available interventionists. Finally, open necrosectomy
is now less often employed, but is the traditional approach for
debridement, and used most often when previous approaches have
failed or the patient requires abdominal exploration for other reasons (Fig. 8).
Long-term sequelae
In addition to the potentially severe acute illness, necrotizing
pancreatitis is accompanied by several potential long-term complications, many of which are related to necrosectomy.1,4,47 Though
percutaneous drains are sometimes adequate, necrosectomy is
often necessary for complete debridement. Without source control
of infected pancreatic necrosis, mortality is extremely high;
necrosectomy reduces this mortality rate dramatically and is thus
an essential procedure in many cases.48 The necessity of this procedure makes characterization of long-term complications similarly essential. Sequelae are often related to the degree of
necrosectomy and amount of remaining functional pancreatic tissue. In a retrospective study of acute necrotizing pancreatitis patients who underwent necrosectomy, Connor et al. showed that
62% of patients developed multiple late complications, including
diabetes mellitus (33%), exocrine pancreatic insufﬁciency (25%),
pancreatic ﬁstula (13%), pseudocyst (8%), delayed ﬂuid collection
(5%), biliary stricture (6%), gastrointestinal stricture (2%), and incisional hernia (2%).49 Hemorrhage is an additional late complication
in up to 6% of patients with necrotizing pancreatitis and can occur
within the gastrointestinal tract, peritoneal cavity, or pancreatic
parenchyma.4
Pancreatic endocrine dysfunction manifests as new-onset diabetes. In a systemic review and meta-analysis consisting of 31
studies and 13,894 patients, Zhi et al. showed that new onset diabetes is frequently seen in patients with severe acute pancreatitis,
acute necrotizing pancreatitis, and alcoholic pancreatitis. Factors
associated with an increased incidence of new-onset diabetes
included severe vs mild acute pancreatitis (39% vs 14%), presence vs
absence of pancreatic necrosis (37% vs 11%), and alcoholic vs biliary
etiology (28% vs 12%). The use of insulin therapy was required in
21% and 18% of severe acute pancreatitis and alcoholic acute
pancreatitis, respectively.50 Tu et al. assessed endocrine and

Fig. 4. Computed tomography scan demonstrating percutaneous drain placed by
interventional radiology for treatment of infected pancreatic necrosis. The trajectory
was chosen to guide future minimally invasive surgical approaches.
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Fig. 5. Video-assisted retroperitoneoscopic debridement for infected pancreatic necrosis. a) Completion view via laparoscope of retroperitoneum. b) Pancreatic necrosis that was
removed piecemeal.

exocrine pancreatic function of discharged patients with acute
pancreatitis. On multivariate logistic regression, pancreatic necrosis
<30%, presence of walled-off necrosis, and insulin resistance were
protective of endocrine pancreatic insufﬁciency.51 Pancreatic
endocrine function may be assessed through oral glucose tolerance
test, homeostatic model assessment-beta and C-peptide levels.
Homeostatic model assessment is used to quantify beta-cell function and insulin resistance. Treatment usually involves insulin
supplementation as the disease process mimics type 1 rather than
type 2 diabetes mellitus.
Acute severe pancreatitis, necrotizing pancreatitis and alcoholic
pancreatitis are associated with a higher incidence of developing
pancreatic exocrine insufﬁciency.52 Furthermore, the development
of exocrine dysfunction correlates with the extent of pancreatic
necrosis and the severity of pancreatic endocrine dysfunction.53
Pancreatic exocrine insufﬁciency was more frequent in alcoholic
pancreatitis compared to biliary pancreatitis and other etiologies.54,55 Pancreatic exocrine function is typically assessed by
measuring the fecal pancreatic elastase-1 level. Garip et al. showed
lower fecal pancreatic elastase-1 levels in patients with severe
acute and necrotizing pancreatitis, pancreatic head necrosis, neartotal necrosis, and in post-necrosectomy patients.52 Treatment is
with pancreatic enzymatic supplementation. Some have reported,
however, that pancreatic exocrine and endocrine dysfunction
following an episode of acute necrotizing pancreatitis may be
transient, with complete recovery achieved in some cases within a
few years.56
The long-term vascular complications of pancreatitis include
hemorrhage secondary to arterial erosion and pseudoaneurysm,
ischemic complications, and venous splanchnic thrombosis.57
These vascular incidents are associated with high morbidity.58

More than half of the patients with acute necrotizing pancreatitis
will develop vascular abnormalities.57 It is believed that the inﬂammatory reaction associated with pancreatitis compresses
adjacent vessels and activates the coagulation cascade. Given its
close proximity to the pancreas, splenic artery erosion and pseudoaneurysm formation is relatively common.58 Acute mesenteric
venous thrombosis is a rare but extremely morbid complication of
pancreatitis, with mortality rates approaching 90% in the presence
of bowel ischemia.59 Early diagnosis and treatment are crucial.
Diagnoses of vascular abnormalities are best achieved with
contrast-enhanced multiphasic computed-tomography scan, with
the portal venous phase diagnosing mesenteric thrombosis, and
arterial phase diagnosing incidental pseudoaneurysms that may
complicate the decision to anticoagulated. Ruptured pseudoaneurysms are most commonly treated with endovascular embolization of feeding vessels. In cases of extremis, open control of
hemorrhage may be necessary. Treatment of mesenteric thrombosis is with anticoagulation, with surgery reserved for bowel
compromise. In the case of the patient with concurrent hemorrhagic pancreatitis or pseudoaneurysms and acute mesenteric
venous thrombosis there is no accepted algorithm for treatment;
clinicians must weigh risks and beneﬁts to decide which issue
poses a more immediate threat to life.
In addition to vascular erosion, necrotizing pancreatitis and its
associated inﬂammation can lead to ﬁstula formation to surrounding gastrointestinal structures. It has not yet been clariﬁed
whether infection causes further inﬂammation that results in ﬁstula formation, or if microscopic ﬁstula is the etiology for many
cases of infected necrosis.60 Regardless, gastrointestinal ﬁstula
formation may be a more common occurrence than has been previously reported. In one observational study, 928 patients were

Fig. 6. Computed tomography scans before and after video-assisted retroperitoneoscopic debridement (VARD) of infected pancreatic necrosis.
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Fig. 7. Images of endoscopic necrosectomy for infected pancreatic necrosis. a) Purulence visualized in stomach after deployment of metal trans-gastric stent. b) Pancreatic necrosis
within the retroperitoneum. c) Trans-gastric drains within the stomach. d) Trans-gastric drains visualized within the retroperitoneum.

admitted for necrotizing pancreatitis and 119 (12.8%) patients
developed a gastrointestinal ﬁstula; 160 total ﬁstulae were identiﬁed.61 Pancreaticocolonic ﬁstula was most common (72, 45.0%),
followed by pancreaticoduodenal ﬁstula (53, 33.1%). Several patients developed pancreatic ﬁstulae to multiple organs (36,
22.5%).61 Treatment is usually non-surgical, with a combination of
percutaneous drainage and optimization of nutritional status to aid
in spontaneous closure. If this fails, surgical options may be
considered, but must be weighed against the risk of new ﬁstula
creation. In the series mentioned, upper gastrointestinal ﬁstulae
were all managed non-surgically, and 65.3% of pancreaticocolonic
ﬁstulae were treated with diverting ostomy formation.61 If ﬁstulae
have matured and there is no ongoing extraluminal contamination,

ﬁstulae may be asymptomatic and not require any intervention.
Pancreatic necrosis is an independent risk factor for developing
recurrent pancreatitis and chronic pancreatitis.62 Repetitive
inﬂammation and necrosis, as seen in recurrent pancreatitis, leads
to glandular scarring, ﬁbrosis and resultant ductal obstruction
observed in chronic pancreatitis. This etiologic linkage is further
supported by the necrosis-ﬁbrosis theory.63 Furthermore, the
Sentinel Acute Pancreatitis Event theory hypothesizes that sentinel
pancreatitis sensitizes the pancreas to permanent ﬁbrosis, and
recurrent episodes result in progressive inﬂammation and ﬁbrosis
that affects glandular structure and function.64 In a large multicenter cross-sectional cohort study of 669 patients with ﬁrst episodes of acute pancreatitis, Ahmed Ali et al. found that ﬁrst
episodes of acute pancreatitis led to recurrent pancreatitis in 17% of
patients; 8% subsequently developed chronic pancreatitis within 5
years.62 In another study that followed patients after sentinel acute
pancreatitis for a 20-year period, the rate of recurrent pancreatitis
was 16.5% and progression to chronic pancreatitis was seen in 13%
and 16% of patients at 10 and 20 years, respectively.65 Independent
risk factors associated with the development of chronic pancreatitis
included male sex, alcohol as the etiology, smoking, severity of ﬁrst
episode, necrotizing pancreatitis, organ failure, modiﬁed Glasgow
score, surgical intervention, and recurrent pancreatitis. Necrotizing
pancreatitis, alcoholic etiology, and recurrent pancreatitis were
found to be independent predictors of developing chronic
pancreatitis.62
Conclusion

Fig. 8. Open necrosectomy for infected and hemorrhagic necrotizing pancreatitis. The
lesser sac is open and exposed with abdominal viscera retracted.

Necrotizing pancreatitis is an often-severe disease process that
may cause severe systemic illness requiring intensive management.
Historical dogma regarding several therapeutic strategies has been
debunked in the past several decades, but mortality for patients
with the disease remains high. Appropriate recognition and
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treatment are necessary to optimize short- and long-term
outcomes.
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